Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.46 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | GOT1 | P17174 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8306406 | 0.91 | TRPV1 (0.43) | TAS1R3TAS1R1TAS1R2TRPV1LMNA | |
| SCHEMBL6927639 | 0.86 | TAS1R3 (0.44) | TAS1R3TAS1R1TAS1R2TRPV1LMNA | |
| SCHEMBL6929369 | 0.83 | ALDH1A1 (0.40) | TAS1R3TAS1R1TAS1R2LMNASMN1; SMN2 | |
| SCHEMBL8301982 | 0.80 | TRPV1 (0.40) | TRPV1LMNASMN1; SMN2NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL6770312 | 0.79 | KDM4E (0.45) | NPC1RAB9AALDH1A1POLB | |
| SCHEMBL8307416 | 0.77 | POLB (0.44) | LMNASMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL6928344 | 0.77 | LMNA (0.39) | TAS1R3TAS1R1TAS1R2LMNANPC1 | |
| SCHEMBL8334448 | 0.77 | SMN1; SMN2 (0.40) | LMNASMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL7103364 | 0.77 | TAS1R3 (0.53) | TAS1R3TAS1R1TAS1R2LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6769510 | 0.76 | POLB (0.43) | LMNASMN1; SMN2NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030153763-A1 | Pharmaceutically active compounds and methods of use | WYETH | 2003-08-14 | — | — | US | claimed |
| US-6514990-B2 | Fused N-heterocylic rings substituted at the ring nitrogen with group of formula (R-N(-R1)-C(=NH)-); treating a neurodegenerative disease; N-(m-ethylphenyl)-1-indolinylcarboximidamide, for example | SCION PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | claimed |
| US-20020099084-A1 | Pharmaceutically active compounds and methods of use | WYETH | 2002-07-25 | — | — | US | claimed |
| EP-0925300-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-06-30 | — | — | EP | claimed |
| EP-0925300-A4 | — | — | 1999-06-30 | — | — | EP | claimed |
| WO-1997030054-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-08-21 | — | — | WO | claimed |
| WO-1999002145-A1 | COMBINATION DRUG THERAPIES COMPRISING AMINOGLYCOSIDE ANTIBIOTICS AND N,N'-DISUBSTITUTED GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153763-A1 | Pharmaceutically active compounds and methods of use | ACHE, PARK7, NLN | TAS1R3 3854/4885TAS1R1 4499/4885TAS1R2 4360/4885 |
| US-20020099084-A1 | Pharmaceutically active compounds and methods of use | ACHE, PARK7, NLN | TAS1R3 3854/4885TAS1R1 4499/4885TAS1R2 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.